Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
EU CTIS ID: 2023-507870-42-00
What this study is testing
To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Be aged between 18 and 75 years (both inclusive).
- Have had COVID-19 at least 3 months before joining the study.
- Have been diagnosed with active PCS (Long COVID).
- Have ongoing problems with memory or concentration due to long-COVID syndrome.
- Show signs of cognitive impairment in study assessments.
- Be willing to complete study assessments.
You likely can't join if
- Have an active or recent COVID-19 infection.
- Have other medical conditions that could explain their symptoms.
- Have severe lung, heart, liver, kidney, or bone disease
- Have a body mass index (BMI) greater than 40 kg/m²
- Are unable to walk or attend study visits.
- Use substances or medications that may affect memory or concentration.
See the full eligibility criteria
- Be aged between 18 and 75 years (both inclusive).
- Have had COVID-19 at least 3 months before joining the study.
- Have been diagnosed with active PCS (Long COVID).
- Have ongoing problems with memory or concentration due to long-COVID syndrome.
- Show signs of cognitive impairment in study assessments.
- Be willing to complete study assessments.
- Be able to understand and speak Spanish.
- Provide written consent to participate.
- Indication of brain fog symptoms: BFS (Brain Fog Scale) ≥ 47
- Have an active or recent COVID-19 infection.
- Have other medical conditions that could explain their symptoms.
- Have severe lung, heart, liver, kidney, or bone disease
- Have a body mass index (BMI) greater than 40 kg/m²
- Are unable to walk or attend study visits.
- Use substances or medications that may affect memory or concentration.
- Major depressive disorder or severe anxiety disorder, according to DSM-5-TR criteria: Scores ≥ 20 on the BDI-II or ≥ 11 on the HADS at screening, followed by the confirmation of the diagnosis by a health professional (psychologist or psychiatrist).
- Are taking medicines that may interact with the study treatment.
- Have a known allergy to rimonabant.
- Have taken part in another clinical trial within the last month.
- Are pregnant or breastfeeding.
- Are able to become pregnant or father a child and are not using effective contraception.
- Have a high risk of suicide.
- Have severe mental health conditions (as per clinical records): major depressive disorder; severe anxiety disorder; bipolar disorder; schizophrenia or schizoaffective disorder; psychotic disorder; previous suicide attempt; any psychiatric disorder requiring psychiatric hospitalization; any other severe psychiatric condition that, in the investigator's opinion, may compromise participant safety or interfere with study
- Have neurological conditions that may affect memory or concentration.
The study team makes the final eligibility decision.
Where it's taking place
- Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.